Member Info for jdt1990

ODXs version of captain Stanley - jog on

It’s not been orderly since April. A company with so many exciting avenues developing well but only priced based on LFT news.
Will be glad when this is all out in the open and we can get on with talking about something else!

LLP sorry I wasn’t correcting you haha that was just me typing my realisation they were linked :)

Sorry that’s Affyxell....literally had the series A financing news this week haha! Been a long week!
Just shows how much we’ve got going on in the background doesn’t it that when you can’t keep up.
Series A financing would suggest the investors like what they see!
One to watch...

Wonder what is going on with the ACE2 therapy. That's gone very quiet....
https://avacta.com/update-on-affimer-therapy-for-covid-19-infection/
Was reading an interesting piece in the bmj about impacts of "long Covid" on younger people. Surely once they get the most vulnerable vaccinated and start to let people out and about again this will be the next area of focus. Stopping the longer term effects of the disease. Might not kill you, but a vaccine or no vaccine doesn't stop you contracting it and not sure I fancy organ damage or developing diabetes!
https://www.bmj.com/content/371/bmj.m4470

Sadly MrTom.....unless you bought on the primary market your money hasn’t gone to AVCT. It’s just being recycled through the secondary market.
Sentiment is there though so wish you all the best.

Incredibly original MrTom!

Sell this ISA holding to pay off the debts and keep the SIPP hoping for the dividends.

Problem for poundcake when he shows up is how does he explain he was also ArnoldP.....few going to get busted at the party for multiple IDs!

I reckon he sits there after a week of him and the AVCT team busting their arse with a keg of John Smiths just repeating “Bloody ell no pleasing you lot - if only thou knew what was ont cards. It’s that bloody Boris stopping me tellin thee. Given enough soddin clues though!”

If I had 2 superpowers Kai - it would be infinite cash and hindsight. Been there so many times before sat waiting for a specific even, day after day passes whilst i watch something on my watchlist tick up and up.
Hey ho....2 shots at company changing projects here for £9m mkt cap. Might as well sit it out....

Jeez would be a hell hole that party - a bunch of PI's sat there shouting "where's my gravy" / "is it ready yet"!

There were clearly some issues around the saliva test and it was also well publicised there were concerns over saliva as a medium in general. In hindsight probably an error to put all the focus on that in the first instance. However, that has happened and we are where we are. Absolutely no suggestion it has been ditched completely from the 23rd Nov RNS.

Why the switch to incorporate the AN test? IMO the only logical answer is the govt had a plan and saliva just didn't fit in with that. In the same way they have ditched nasopharyngeal it would seem. To produce in the scale the govt want to, it has to be a consistent process. AS has to switch to get in on the testing strategy we are now seeing emerge. The govt were no way going to wait for a saliva test....
So the AN is what the govt want now. What's not to say the saliva needs more refining and further down the line the govt see it is superior (just not in its current form) or even saliva ends up being for the private market? As must see something in it to continue and run in parallel rather than abandon.

"In preparation for clinical validation of the lateral flow test Avacta is working on both saliva and anterior nasal swab samples. Anterior nasal swabs sample the easily accessible parts of the nose and are therefore painless and straightforward to administer, unlike nasopharyngeal swabs which are generally regarded as painful and unpleasant. Avacta and its partners will continue to develop both sampling methods in parallel in order to bring high performance COVID-19 tests to market quickly to suit a range of use cases."

Livedata - I put this proposition to xxxyyyzzz the other day when they were having a hissy fit. We know once a sovereign test is released (which it is pretty clear that is close to fruition) that Innova will get absolutely zero future sales. The scrutiny and stick their test has come under will mean they have just done a great job at a smash and grab "del boy" style back of a van product. Where nothing else was available, it did a job (albeit shoddy job).
Now - we know how much money is going into the testing programmes globally £22bn in the uk and $50bn in the US, so we can safely say the market is $100Bn plus minimum globally.
So I ask you this. Would you want £1bn in the bank now, a reputation that is completely shot, no future sale prospects (and in AVCTS case IP that is showing significant promise being discredited due to a cr*p LFT)
OR
A later than planned but "Gold Standard" LFT and other Covid products (Assuming AVCTs test is a s good as AS says) which puts us in the queue for a $100bn+ market. You need to capture 1% of that to make that back. A strong reputation to build a business around very promising IP, future licensing deals, a therapeutics business?
No to mention if this test is as good as AS says it is, it puts Affimers firmly on the map!
I know my answer.....and a clue, its not the first one

And the fact we have heard nothing material on BAMS/LFT or ELISA just makes me think more and more Avct are part of a wider government "we can't let this happen again" plan. Looking at the website we have a product for mass screening (home/POC), hospital/lab setting and also research into understanding the virus. Covers all the bases.

"Avacta is supporting global efforts in combating the COVID-19 pandemic by using its Affimer® platform to develop diagnostics for COVID-19 antigen testing.
Avacta has generated a large number of Affimer binders to the SARS-COV-2 virus spike protein including Affimer pairs for sandwich assays and Affimer inhibitors of the spike-ACE2 interaction.

Avacta is developing a number of SARS-COV-2 tests:
A rapid point-of-care test intended for screening of large populations to diagnose the COVID-19 coronavirus infection.
A high throughput laboratory test for the infection, to run on the installed base of mass spectrometers in hospitals and laboratories.
An ELISA laboratory test to support global research efforts into the coronavirus that causes COVID-19.
Avacta’s COVID-19 programmes are rapidly evolving. Please see the further information below or contact us via the web form."

From 23rd Nov RNS - That doesn't really suggest BBI issues to me. IMO AN pivot is most likely a govt driven change which Avct knew they had to take on to be in the mixer there. Too much work to do on saliva to have it ready / validated in a short timeframe. It just didn't fit the "sovereign test" plan.
"The development of an Affimer-based lateral flow antigen test that can be manufactured at scale being carried out in partnership with BBI Solutions has made substantial progress. A highly scalable test device using readily available components and routine manufacturing processes has now been shown to have a sensitivity for coronavirus spike protein in laboratory samples better than 300 pg/ml which is in the range expected for spike protein in clinical samples."

Hi KEY2 - As with all aim stocks there is a element of sentiment. Which has been pretty negative over the years with LCs inability to get anything off the ground and dilute shareholders to oblivion.
Today’s RNS is a step in the right direction for sure. Your fundamental numbers on paper can’t be argued with. However, LC has moved any assets of value out of direct Kibo ownership and into new companies. It would have been nice to get a shareholding in those as a Kibo holder but that never happened.
I think the hesitation/caution here is two fold:
1. Placings/raises that he couldn’t get away with here are possible in both Kat and Med which would dilute the Kibo ownership and value. He’s got history.
2. There is still nothing revenue generating in kibo itself. You can’t really run a business on holdings in other companies and the hope warrants are exercised to fund it. It needs some genuine revenue to run and grow.
Sentiment is coming back but it will take a bit of time to recover.
Hopefully KAT gets Blyvoor funded and some good haneti news which will give this a boost.
As others have said, one Africa project comes to fruition and this is a different ball game.

Couldn't agree more LUKE.
Not sure how current SP action is ugly. It was bumbling along in the 150-175 range in anticipation of LFT news, vaccine news dropped and we took an excessive hit which hasn't fully recovered, now trading in the 125-150 range again in anticipation of that same LFT news.
It's taken longer than we all anticipated.
Plenty going on while we wait strengthening the fundamentals of this business.
AS has said he is happy with S&S and we will sell every test we will make. There is a big difference between overegged timelines and making statements like that on your products if they weren't true.
There's clearly a good reason for the silence - we just have to wait and find out - and I don't think that reason is the tests don't work!

I have an average of around 2.5p, same as you couldn’t really just throw more money at averaging down when very little progress was being made.
This is one good news and every little helps in getting back to near that for an exit.
Good luck to those who got in low!
Now he’s offloaded another set of assets to a standalone company I just hope he doesn’t dilute MED to oblivion at the expense of KIBO shareholders and can actually get something of the ground directly in KIBO to provide some revenue and direct value in this share.

DVN broker note 33p risked - 66p derisked.....and the risk reduces at HAV on a 6 week basis!